Finance

Lists
Q1 2027 earnings • released • EPS miss -79.05% • Revenue beat +46.96%
See results
ANAB:NASDAQ
AnaptysBio Inc
$46.25
-3.18%
(-1.52) 1D
$46.25
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ANAB...
Open
$45.27
High
$47.36
Low
$44.64
Mkt. cap
1.38B
Avg. vol.
442.82K
Volume
499.64K
52-wk high
$72.36
52-wk low
$21.93
Beta
0.37
Shares outstanding
29.90M
No. of employees
104
Open
$45.27
High
$47.36
Low
$44.64
Mkt. cap
1.38B
Avg. vol.
442.82K
Volume
499.64K
52-wk high
$72.36
52-wk low
$21.93
Beta
0.37
Shares outstanding
29.90M
No. of employees
104
News stories
From web sources and news partners
About AnaptysBio Inc
CEO-
Employees104
Founded2005
HeadquartersSan Diego, California, United States
SectorHealth Care
IndustryBiotechnology
Websiteanaptysbio.com
Analyst ratings
Based on 7 analysts giving stock ratings to ANAB in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for ANAB in the last 3 months.
Highest
Current $46.25
$95.00 (+105.41%)
Average
$80.00 (+72.97%)
Lowest
$60.00 (+29.73%)
Analyst
Recommendation
Action
Price target
Projected
Date
Etzer Darout
Barclays
Buy
Maintained
$75.00
+62.2%
11/13/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$93.00
+101.1%
11/13/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$95.00
+105.4%
11/13/2026
David Risinger
Leerink Partners
Buy
Maintained
$81.00
+75.1%
10/21/2026
Anupam Rama
J.P. Morgan
Buy
Reiterated
$60.00
+29.7%
09/30/2026
Michael Yee
UBS
Buy
Reiterated
$76.00
+64.3%
09/22/2026
Joseph Thome
TD Cowen
Buy
Reiterated
-
-
08/25/2026
David Nierengarten
Wedbush
Buy
Reiterated
$75.00
+62.2%
03/31/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
$66.00
+42.7%
03/30/2026
Joon Lee
Truist Financial
Hold
Maintained
$50.00
+8.1%
03/09/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$85.00
+83.8%
03/05/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$140.00
+202.7%
03/04/2026
Last report
Nov 12, 2026
Fiscal period
Q1 2027
$0.11 / $0.52
-79.05%miss
Revenue / Est. (USD)
30.27M / 20.60M
+46.96%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Mar 2026
Jun 2026
Jun 2026
Sep 2026
Revenue
25.56M
27.49M
27.49M
30.27M
Cost of goods sold
33.99M
-2.70M
-
-
Cost of revenue
33.99M
-2.70M
-
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26.20M
15.52M
-
-
Operating expense
26.20M
15.52M
-
-
Total operating expenses
60.19M
12.81M
-
-
Operating income
-34.64M
14.67M
-
-
Other non operating income
-1.00K
-1.00K
-
-
EBT including unusual items
-52.84M
-4.17M
-
-
EBT excluding unusual items
-52.84M
-4.17M
-
-
Income tax expense
40.00K
-181.49M
-
-
Effective tax rate
-0.08%
4,348.13%
-
-
Other operating expenses
-
-
-
-
Net income
-52.88M
183.88M
-
-
Net profit margin
-206.93%
668.95%
-
-
Earnings per share
-1.84
-
4.93
0.11
Interest and investment income
2.65M
1.49M
-
-
Interest expense
-20.86M
-20.33M
-
-
Net interest expenses
-18.21M
-18.85M
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-34.51M
14.68M
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps